Pliant Therapeutics, INC Form 4 insider transactions

Robert Iannone, a Director of Pliant Therapeutics, Inc., received 60,000 shares of common stock on July 9, 2026.

Flavia Borellini, a Director of Pliant Therapeutics, Inc., received 60,000 shares of common stock on July 9, 2026.

Director Gayle A. Crowell was granted 70,000 stock options in Pliant Therapeutics, Inc. as part of a standard equity compensation arrangement.

Director Thomas A. McCourt was granted 70,000 stock options in Pliant Therapeutics, Inc. as part of standard equity compensation.

Director Steve E. Krognes was granted 70,000 stock options in Pliant Therapeutics as part of standard equity compensation.

Pliant Therapeutics director John T. Curnutte was granted 70,000 stock options as part of his compensation package.

Director Hoyoung Huh was granted 70,000 stock options in Pliant Therapeutics as part of standard equity compensation.

Director Darren S. Cline was granted 70,000 stock options in Pliant Therapeutics, Inc. as part of a standard equity compensation package.

Pliant Therapeutics COO Minnie Kuo participated in a board-approved stock option repricing program effective April 17, 2026.

Pliant Therapeutics CFO Keith Lamont Cummings participated in a company-wide stock option repricing program on April 17, 2026.

Pliant Therapeutics CEO Bernard Coulie has repriced multiple tranches of stock options to $1.33 per share following board approval.

Pliant Therapeutics Chief Human Resource Officer Lily Cheung reported a repricing of existing stock options to $1.33 per share.

Pliant Therapeutics' Chief Financial Officer, Keith Lamont Cummings, was granted 400,000 stock options with an exercise price of $1.30, vesting monthly over four years.

Pliant Therapeutics' Chief Operating Officer, Minnie Kuo, was granted 300,000 stock options with an exercise price of $1.30, vesting monthly over four years.

Pliant Therapeutics' Chief Human Resource Officer, Lily Cheung, was granted 300,000 stock options with an exercise price of $1.30, vesting monthly over four years.

Pliant Therapeutics' President and CEO, Bernard Coulie, acquired 1,230,000 stock options with an exercise price of $1.30, vesting monthly over four years.

Pliant Therapeutics' Chief Financial Officer, Keith Lamont Cummings, sold 24,002 shares of common stock to cover tax liabilities from vested restricted stock units.

Pliant Therapeutics' Chief Human Resource Officer, Lily Cheung, sold 7,534 shares of common stock at a weighted average price of $1.28 to cover tax liabilities from RSU vesting.

Pliant Therapeutics' President and CEO, Bernard Coulie, sold 89,375 shares of common stock to cover tax liabilities from vested restricted stock units.

Pliant Therapeutics' Chief Operating Officer, Minnie Kuo, sold 6,917 shares of common stock at an average price of $1.28 to cover tax liabilities from restricted stock unit vesting.

Pliant Therapeutics, Inc. Director Suzanne Louise Bruhn was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year.

Pliant Therapeutics, Inc. director Katharine Knobil was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year, as disclosed in a recent SEC Form 4 filing.

Pliant Therapeutics, Inc. (PLRX) Director Thomas A. McCourt was granted 30,000 stock options with an exercise price of $1.61, vesting over time, as reported in a recent SEC Form 4 filing.

Pliant Therapeutics, Inc. Director John T. Curnutte was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year.

Pliant Therapeutics, Inc. Director Steve Krognes was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year, as disclosed in a recent SEC Form 4 filing.

Pliant Therapeutics, Inc. Director Darren Cline was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year, as disclosed in a recent SEC Form 4 filing.

Pliant Therapeutics, Inc. Director David E.I. Pyott was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year, as reported in a recent SEC Form 4 filing.

Pliant Therapeutics, Inc. director Hoyoung Huh was granted 30,000 stock options with an exercise price of $1.61, vesting over approximately one year.

Pliant Therapeutics, Inc. Director Gayle Crowell was granted 30,000 stock options with a strike price of $1.61, vesting over time, as reported in a recent SEC Form 4 filing.

Pliant Therapeutics' Chief Human Resource Officer, Lily Cheung, received stock and option grants as part of her compensation package.